Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: TMT
Ebiquity’s year-end trading update indicates FY18 performance across both the continuing and the now-sold Advertising Intelligence businesses in line with management expectations. Given the delay and uncertainty over the disposal on the CMA referral, this is a solid outcome. FY19 will see some effect of overheads taking time to scale down following the AdIntel sale, which offsets underlying profit improvement. The core consulting business has good potential globally and the reinforced management team can now focus its efforts on driving growth and improving returns, aided by a strengthened balance sheet.
Ebiquity |
FY18 performance as anticipated |
Year-end trading update |
Media |
12 February 2019 |
Share price performance
Business description
Analysts
Ebiquity is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||
Ebiquity’s year-end trading update indicates FY18 performance across both the continuing and the now-sold Advertising Intelligence businesses in line with management expectations. Given the delay and uncertainty over the disposal on the CMA referral, this is a solid outcome. FY19 will see some effect of overheads taking time to scale down following the AdIntel sale, which offsets underlying profit improvement. The core consulting business has good potential globally and the reinforced management team can now focus its efforts on driving growth and improving returns, aided by a strengthened balance sheet.
Year end |
Revenue (£m) |
EBIT (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/16 |
83.6 |
13.0 |
11.8 |
11.3 |
0.65 |
5.4 |
1.1 |
12/17 |
87.4 |
12.0 |
11.0 |
9.4 |
0.71 |
6.5 |
1.2 |
12/18e |
89.0 |
7.6 |
6.3 |
6.2 |
0.75 |
9.9 |
1.2 |
12/18e* |
69.0 |
5.9 |
5.5 |
4.5 |
0.75 |
13.7 |
1.2 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, share-based payments Note: *Pro-forma as if Ad Intel disposed for FY18.
The update states that the underlying consulting business grew 8% in FY18 and management is targeting a similar rate of growth in FY19, implying revenues from the continuing business of around £74m. The underlying divisional breakdown would suggest that the ongoing business should show improving margins over time with the change in mix. However, margins will be constrained in FY19 by the requirement to keep covering some of the Ad Intel costs under the terms of the agreement with Nielsen. We expect that the extent and duration of this obligation will be clarified at the prelims. Management guidance for now is that there will be limited, if any, uplift in profitability in FY19. Beyond that horizon we expect operating margin progress, driven primarily by improving profitability in the Analytics and Tech business as this matures.
Ebiquity now has an experienced permanent CFO/COO in Alan Newman (recently retired from YouGov) and has also been strengthening its operational management team. There will doubtless be a focus on aligning the group’s cost base to the Media, Analytics and Tech consulting business. The balance sheet has been considerably bolstered by the disposal, which completed two days into the new financial year. Net debt at 31 December 2018 was £28m; the proceeds will have reduced that figure by around £20m.
|
Disclaimer
|
|
Disclaimer
|
Orexo’s FY18 results demonstrated continuing profitability derived from its lead product, Zubsolv, responsible for 21.7% y-o-y net sales growth driven by US Zubsolv Q418 prescription and revenue growth of 22% and 31.8%, respectively. The weakness in partnered products compared to our targets (although FY18 partnered sales were SEK125.4m) and higher Q4 investment (including litigation) reduced FY18 EPS compared to our estimate by SEK1.8. We have tempered our revenue growth expectations for FY19 until the impact of Suboxone film generics is known.